Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Eye, Published online: 18 July 2019; doi:10.1038/s41433-019-0522-zRelationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data (Source: Eye)
Source: Eye - July 18, 2019 Category: Opthalmology Authors: Srinivas R. Sadda Joanna Campbell Pravin U. Dugel Nancy M. Holekamp Szil árd Kiss Anat Loewenstein Albert J. Augustin Vanessa Shih Xiaoshu Xu Charles C. Wykoff Scott M. Whitcup Source Type: research

Innovative therapies for neovascular age-related macular degeneration.
Authors: Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU Abstract Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial. Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, ...
Source: Expert Opinion on Pharmacotherapy - July 13, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Soluble Tei2 fusion protein inhibits retinopathy of prematurity occurrence via regulation of the Ang/Tie2 pathway.
In conclusion, the combined regulation of the Ang/Tie2 and the vascular endothelial growth factor (VEGF)/VEGF receptor pathways markedly increased the efficacy of treatment with retinal neovascularization (RNV). Regulation of these pathways has a potential for treating RNV, in particular ROP. PMID: 31258697 [PubMed] (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - July 3, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research

Intravitreal Ranibizumab With Panretinal Photocoagulation Followed by Trabeculectomy Versus Visco-Trabeculotomy in Management of Neovascular Glaucoma
Conclusions: Both VT and Trab-MMC groups are effective in reducing the IOP in cases of NVG after control of neovascularization with anti-vascular endothelial growth factor and pan retinal photocoagulation. (Source: Asia-Pacific Journal of Ophthalmology)
Source: Asia-Pacific Journal of Ophthalmology - July 1, 2019 Category: Opthalmology Tags: Original Clinical Study Source Type: research

Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
Abstract When evaluating the impact of vision-destroying diseases, pharmacologic therapies represent a significant cost to patients, insurance providers, and society. Currently, up to 11 million people in the United States have some form of age-related macular degeneration (AMD), which is one of the leading causes of vision loss in older Americans. Ophthalmologists have administered more than 6 million intravitreal injections of aflibercept, bevacizumab, pegaptanib, and ranibizumab last year. Comprehensive assessment requires managed care administrators and clinicians to understand the direct and indirect costs of...
Source: The American Journal of Managed Care - July 1, 2019 Category: Health Management Authors: Cannon E Tags: Am J Manag Care Source Type: research

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity.
Authors: Chen X, Zhou L, Zhang Q, Xu Y, Zhao P, Xia H Abstract Background: Retinopathy of prematurity (ROP) is one of the common complications of prematurity. Intravitreal injection of ranibizumab (IVR), an antivascular endothelial growth factor (VEGF) drug, showed significant benefit for ROP. However, there are concerns about systemic complications of anti-VEGF therapy in preterm infants. Objectives: To evaluate serum VEGF level in the systemic circulation after IVR and the complications associated with IVR for the premature infants with ROP. Methods: This prospective investigation assessed the serum conce...
Source: Journal of Ophthalmology - June 28, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats
In conclusion, the PEGDM/COL sheet device suppressed CNV via a transscleral administration route for 18 weeks, indicating that prolonged sustained ranibizumab release could reduce the burden of repeated intravitreal injections.Graphical abstract (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - June 25, 2019 Category: Drugs & Pharmacology Source Type: research

ACCURACY AND PRECISION OF INTRAVITREAL INJECTIONS OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN REAL LIFE: What Is Actually in the Syringe?
Purpose: To evaluate the accuracy and precision of anti–vascular endothelial growth factor volume delivery by intravitreal injections in the clinical setup. Methods: Volume output was measured in 669 intravitreal injections administered to patients, calculated from the difference in syringe weight before and after expelling the drug. Three groups were included: prefilled bevacizumab 1.0 mL syringe (Group 1, n = 432), pre-filled ranibizumab in a small-volume syringe with low dead-space plunger design (Group 2, n = 125), and aflibercept drawn and injected using a 1.0-mL syringe (Group 3, n = 112). Accuracy was ana...
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial
Purpose: To prospectively investigate the injection frequency of aflibercept and ranibizumab in the treatment of macular edema in central retinal vein occlusion. Methods: Patients with treatment-naive central retinal vein occlusion and macular edema were randomized to receive intravitreal injections with aflibercept (n = 22) or ranibizumab (n = 23) in a treat-and-extend regimen with a follow-up time of 18 months. After 3 loading doses, the treatment intervals were extended by 2 weeks to a maximum of 12 weeks. Intervals were shortened by 2 weeks if macular edema recurred. Results: The number of injections was signif...
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result
Conclusion: The combination therapy of IVR and SMLP can treat branch retinal vein occlusion cystoid macular edema effectively, by decreasing the frequency of IVR injections while maintaining good visual acuity. (Source: RETINA)
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia
Conclusion: Intravitreal ranibizumab provide a 5-year visual benefit in eyes with myopic CNV compared with the natural course. A lack of enlargement of the CNV-related macular atrophy, a better baseline BCVA, and a minimum number of IVR injections were associated with better visual outcomes. (Source: RETINA)
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
Conclusion: UWFFA-guided TRP reduced the number of injections of Ranibizumab in patients having BRVO with macular edema, while maintaining similar benefits in the improvement of BCVA, central subfoveal thickness without deleterious effect on the visual field, and contrast sensitivity. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - June 25, 2019 Category: Opthalmology Authors: Siddhi Goel Atul Kumar Raghav D Ravani Parijat Chandra Mahesh Chandra Vinod Kumar Source Type: research

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - June 21, 2019 Category: Opthalmology Authors: Fen Tang, Fan Xu, Haibin Zhong, Xin Zhao, Mingliang Lv, Ke Yang, Chaolan Shen, Hui Huang, Jian Lv, Siming Zeng, Min Li and Qi Chen Tags: Research article Source Type: research

Cancers, Vol. 11, Pages 868: Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
nti Ranjbar Despite the implication of vascular endothelial growth factor-A (VEGF-A) in the pathophysiology of uveal melanoma (UM), the anti-VEGF-A antibody bevacizumab yielded conflicting results on UM growth. Here, we evaluated whether bevacizumab and ranibizumab, a humanized Fab-fragment against VEGF-A, can enter UM cells and induce a sustained physiological response. The primary and metastatic UM cell lines Mel-270 and OMM-2.5 were exposed to bevacizumab or ranibizumab for one day and were maintained further in untreated medium for a total of three days. Both antibodies significantly reduced the levels of extrac...
Source: Cancers - June 21, 2019 Category: Cancer & Oncology Authors: Tura Pawlik Rudolf Ernesti Stutzer Grisanti Ranjbar Tags: Article Source Type: research

Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.Med Princ Pract (Source: Medical Principles and Practice)
Source: Medical Principles and Practice - June 19, 2019 Category: Internal Medicine Source Type: research

[Central venous occlusion in Wyburn-Mason syndrome].
Abstract The diagnostic findings, therapy and course of disease are described for a case of central venous occlusion in Wyburn-Mason-Syndrome. The diagnosis was based on OCT, fluorescein angiography and cMRI. In addition, due to the macular edema an intravitreal injection with Ranibizumab was applied. The macular edema regressed and further Ranibizumab-injections as well as a panretinal laser-coagulation and possibly a cryocoagulation were planned. For a central venous occlusion with macular edema also in Wyburn-Mason-Syndrome an intravitreal anti-VEGF-inhibition leads to an improvement. PMID: 31209569 [PubMe...
Source: Der Ophthalmologe - June 17, 2019 Category: Opthalmology Authors: Toepffer AM, Wecke T, Hoffmann MB, Thieme H Tags: Ophthalmologe Source Type: research

Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
CONCLUSIONS: ADRs that affect the eye represented 3.5% of all pharmacovigilance reports during the reporting period. Whereas retinal haemorrhage and uveitis are known adverse reactions to angiogenesis inhibitors, the reported cases of blindness and death should heighten awareness of potential safety issues associated with VEGF inhibitors for the treatment of proliferative eye disorders. PMID: 31256417 [PubMed - in process] (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - June 17, 2019 Category: General Medicine Authors: Karrer JE, Giovannoni L, Kullak-Ublick GA, Weiler S Tags: Swiss Med Wkly Source Type: research

The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice.
Authors: Sever O, Horozoglu F Abstract PURPOSE: To evaluate the effect of single-dose intravitreal dexamethasone (Dx) implant as an adjunctive treatment for patients undergoing anti-vascular endothelial growth factor (anti-VEGF) treatment with poor response. MATERIAL AND METHODS: Eighty-four eyes of 72 patients with non-proliferative diabetic retinopathy and diabetic macular edema with a poor response to 3 loading doses of intravitreal ranibizumab (IVR) were included in this study. Group 1 consisted of forty-four eyes which went on a Pro re Nata (PRN) dose regimen of IVR injections after 3 loading doses of rani...
Source: Journal Francais d Ophtalmologie - June 16, 2019 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - June 13, 2019 Category: Drugs & Pharmacology Authors: Lorenzo Ferro Desideri Fabio Barra Simone Ferrero Carlo Enrico Traverso Massimo Nicol ò Source Type: research

Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study.
Abstract PURPOSE: To investigate vision-related quality of life in patients referred to the Italian Retina Services for intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia. DESIGN: Post hoc analysis of a multicenter, interventional phase IIIb study (OLIMPIC). METHODS: Patients with either previously untreated (naïve) or treated choroidal neovascularization due to pathologic myopia were enrolled. Vision-related quality of life was measured using the Italian version of the Impact of Vision Impairment Questionnaire with scores from 0 (no impact) to 5 (severe imp...
Source: European Journal of Ophthalmology - June 6, 2019 Category: Opthalmology Authors: Virgili G, Parravano M, Viola F, Varano M Tags: Eur J Ophthalmol Source Type: research

Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression
Eye, Published online: 05 June 2019; doi:10.1038/s41433-019-0479-yRanibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression (Source: Eye)
Source: Eye - June 5, 2019 Category: Opthalmology Authors: Ashish Sharma Nilesh Kumar Nikulaa Parachuri Baruch D Kuppermann Bandello Francesco Carl D. Regillo Source Type: research

Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks
Conclusions: In this study, we present the 96-week results, of the largest series to date, of patients treated prospectively with aflibercept for RAP using the VIEW protocol. We show that they benefited from treatment to a degree similar to those with type 1 and 2 nAMD.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 4, 2019 Category: Opthalmology Source Type: research

Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis
Conclusion: This meta-analysis confirms the comparable safety and efficacy of anti-VEGF therapies for patients with cystoid macular oedema secondary to BRVO. There is a need for randomised prospective comparative trials of anti-VEGF agents for BRVO.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 3, 2019 Category: Opthalmology Source Type: research

Choroidal neovascular membrane associated with unilateral retinitis pigmentosa.
Authors: Montoya Delgado MJ, Ríos Nequis G, Ramírez Estudillo A Abstract A 67 year-old woman with diabetes mellitus type 2 no medical background of interest was attended in hospital due to visual loss of left eye of 4 months of onset. The fundus examination revealed findings corresponding to moderate non-proliferative diabetic retinopathy in the right eye and pigmented lesions similar to bone spicules and atrophy of the retinal pigment epithelium in the middle periphery and in the macular area in the left eye. The full-field electroretinogram was flat, with a slight insinuation of the b-wave in the li...
Source: Archivos de la Sociedad Espanola de Oftalmologia - June 1, 2019 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy.
Authors: Zhao LQ, Cheng JW Abstract Aims: To examine possible benefits of intravitreal anti-vascular endothelial growth factor (VEGF) agent treatment immediately after cataract surgery for patients with diabetic retinopathy (DR). Methods: A comprehensive literature search was performed using the Cochrane collaboration methodology to identify randomized controlled trials (RCTs) and comparative studies of cataract surgery with or without anti-VEGF agent treatment for any diabetic retinopathy. Meta-analyses were performed for clinical outcome parameters including changes in macular thickness (MT), best-corrected v...
Source: Journal of Ophthalmology - June 1, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Central retinal venous occlusion in a child with hyperhomocysteinemia: A case report
Rationale: To report a rare case of 8-year-old girl patient with central retinal venous occlusion (CRVO) with hyperhomocysteinemia. Patient concerns: The patient had a 2-year history on painless visual loss in the left eye. Diagnoses: All examination results were within normal limits except plasma homocysteine (HCY). Fluorescein angiography (FA) confirmed peripheral capillary non-perfusion (CNP) in the left eye, and OCT showed macular edema. The girl patient was diagnosed as CRVO. Interventions: Based on all of the test results, laser photocoagulation was performed at peripheral capillary non-perfusion (NP). Ran...
Source: Medicine - June 1, 2019 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema
Conclusion: The addition of a high-rich DHA dietary supplement to intravitreal ranibizumab was effective to achieve better sustained improvement of central subfield macular thickness outcomes after 3 years of follow-up as compared with intravitreal ranibizumab alone. (Source: RETINA)
Source: RETINA - May 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Allergic reaction upon intravitreal administration of anti–vascular endothelial growth factor agents
Conclusion: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - May 23, 2019 Category: Opthalmology Tags: Case Report Source Type: research

One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
Conclusions: Intravitreal injections of conbercept appear to be beneficial in patients with nvAMD who exhibit persistent fluid despite previous treatment with ranibizumab.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - May 23, 2019 Category: Opthalmology Source Type: research

Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy.
Abstract OBJECTIVE: To determine the efficacy of preoperative intravitreal injections of conbercept (IVC) and ranibizumab (IVR) on postoperative best-corrected visual acuity (BCVA), vitreous hemorrhage (VH), and neovascular glaucoma (NVG) in a population with proliferative diabetic retinopathy (PDR) undergoing vitrectomy. DESIGN: Retrospective, cross-sectional study. PARTICIPANTS: 386 patients with severe PDR (428 eyes). METHODS: The patients who did not receive IVC or IVR were assigned to group A (125 eyes), the patients who received IVR (0.5 mg) were assigned to group B (146 eyes), and the patient...
Source: Canadian Journal of Ophthalmology - May 22, 2019 Category: Opthalmology Authors: Lu Q, Lu L, Chen B, Chen W, Lu P Tags: Can J Ophthalmol Source Type: research

Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane.
Authors: Cakir A, Erden B, Bolukbasi S, Aydin A, Yurttaser Ocak S, Maden G, Elcioglu MN Abstract OBJECTIVE: To compare the efficacy and safety of intravitreal ranibizumab (RZB) injections and intravitreal dexamethasone (DEX) implant in diabetic macular edema (DME) with concurrent epiretinal membrane (ERM). METHODS: This was a retrospective, observational, comparative study. Medical records of DME patients with concurrent ERM were retrospectively reviewed. Seventeen eyes of 16 patients treated with 3 consecutive monthly RZB injections (RZB group) and 22 eyes of 18 patients treated with a DEX implant (DEX group) ...
Source: Journal Francais d Ophtalmologie - May 17, 2019 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
AbstractEmerging anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have revolutionised medical retina practice and the management and eventual outcome of nAMD. Recent research has focused on evaluating and comparing the efficacy of the two most widely employed anti-VEGF agents, bevacizumab and ranibizumab; however, a subgroup of patients with nAMD demonstrates a suboptimal response to standard therapy. We have therefore conducted a review of pertinent studies published until August 2018 which have documented the clinical efficacy when switching to a differ...
Source: Advances in Therapy - May 17, 2019 Category: Drugs & Pharmacology Source Type: research

Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration
Conclusions: The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.RESUMO Objetivo: Estudar a efic ácia e segurança dos tratamentos com ranibizumabe e bevacizumabe para a degeneração macular relacionada à idade exsudativa. Métodos: Ensaio clínico paralelo randomizado foi conduzido para comparar a eficácia e segurança de três regimes (bevacizumabe a cada mês, bevacizumabe a cada 2 sema nas e ranibizumabe todos os meses), seguidos por retratamentos co...
Source: Arquivos Brasileiros de Oftalmologia - May 16, 2019 Category: Opthalmology Source Type: research

Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
Abstract OBJECTIVE: To evaluate short term changes in anterior chamber depth (ACD), central corneal thickness (CCT), intraocular pressure (IOP), and corneal endothelial cell density (ECD) after intravitreal anti-vascular endothelial growth factor (VEGF) injections. MATERIALS AND METHODS: A total of 100 eyes from 100 patients, who were naive for intravitreal injection treatment, were included in this retrospective study. Patients who received only a single type of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, or aflibercept) for two consecutive months were examined. ACD, CCT, IOP, and ECD measur...
Source: Cutaneous and Ocular Toxicology - May 15, 2019 Category: Toxicology Authors: Arslan GD, Guven D, Alkan AA, Kacar H, Demir M Tags: Cutan Ocul Toxicol Source Type: research

Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept
To assess whether publication of Comparison of Age-related macular degeneration Treatment Trial (CATT) results and introduction of aflibercept to the marketplace affected intravitreal bevacizumab and ranibizumab utilization.Design: Retrospective analysis of treatment patterns. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - May 14, 2019 Category: Opthalmology Authors: Suzann Pershing, Nidhi Talwar, Stephen T. Armenti, Joseph Grubbs, Julie M. Rosenthal, Vaidehi S. Dedania, Joshua D. Stein Tags: Original Articles Source Type: research

Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Study Group Abstract IMPORTANCE: To provide new insights into aflibercept effect in non-naive-treated patients with neovascular age-related macular degeneration. PURPOSE: To assess the efficacy of intravitreal aflibercept in patients with neovascular age-related macular degeneration without optimal response to previous anti-vascular endothelial growth factor A therapy. DESIGN: Single-arm, multi-centre, prospective study. PARTICIPANTS: Patients ⩾50 years with active neovascular age-related macular degeneration, best-corrected visual acuity between 20/32 and 20/320 with suboptimal response to ranibi...
Source: European Journal of Ophthalmology - May 14, 2019 Category: Opthalmology Authors: Monés J, Biarnés M, Macbeth Study Group Tags: Eur J Ophthalmol Source Type: research

Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis
ConclusionIn conclusion, the results of our meta-analysis demonstrate a transiently synergistic effect of MPC on CMT when this treatment is combined with anti-VEGF agents, whereas no similar synergistic effect could be detected on the BCVA. A relatively longer follow-up was essential to be able to evaluate the long-term existence of this synergistic effect. (Source: Diabetes Therapy)
Source: Diabetes Therapy - May 11, 2019 Category: Endocrinology Source Type: research

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study.
Abstract BACKGROUND: To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected visual acuity (BCVA)
Source: The British Journal of Ophthalmology - May 11, 2019 Category: Opthalmology Authors: Bandello F, Staurenghi G, Ricci F, Midena E, Viola F, Lupieri Sinibaldi T, Colombo L, Peruzzi E, Bassanini S Tags: Br J Ophthalmol Source Type: research

Long-term changes in retinal layers in patients undergoing intravitreal ranibizumab for neovascular age-related macular degeneration
ConclusionsSignificant changes were observed in the thickness of the inner RLs after 1-year treatment with IVRs for n-AMD. A significant decrease in RPE thickness confined to the first months disappeared at month-12. (Source: International Ophthalmology)
Source: International Ophthalmology - May 8, 2019 Category: Opthalmology Source Type: research

Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study)
To evaluate the outcomes and complications of intravitreal injections of ranibizumab in patients during pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. This retrospective, observational, comparative study included 103 patients (103 eyes) who underwent pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. Sixty-six patients received an intravitreal injection of 0.05 mg (0.05 cc) of ranibizumab at the end of surgery. Main outcome measures were the occurrence of recurrent early vitreous hemorrhage, reoperation, intraocular pressure, best corrected visual acuity. Mean follow-up time was 6 ...
Source: Medicine - May 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience
Conclusions: One-third of eyes with DME responded well to PRN treatment strategy from the first month without 3 loading doses of ranibizumab. Baseline visual acuity is the best predictor of vision at 1 and 2 years of follow-up. (Source: Asia-Pacific Journal of Ophthalmology)
Source: Asia-Pacific Journal of Ophthalmology - May 1, 2019 Category: Opthalmology Tags: Original Clinical Study Source Type: research

Subretinal pseudocyst: A novel optical coherence tomography finding in age-related macular degeneration.
CONCLUSIONS: Subretinal pseudocysts are a new structural optical coherence tomography entity. We reported for the first time the evidence that pseudocysts may develop in the subretinal space in a case of age-related macular degeneration. PMID: 31018677 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 25, 2019 Category: Opthalmology Authors: Sacconi R, Mullins RF, Lutty GA, Borrelli E, Bandello F, Querques G Tags: Eur J Ophthalmol Source Type: research

Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy
Purpose: To compare the 6-month efficacy of the intravitreal injection of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective case–control study involved 79 PCV eyes of 77 patients. The PCV eyes were treated with an intravitreal injection of either ranibizumab (n = 44) or conbercept (n = 35). Three monthly loading doses were injected and followed by retreatment as needed. The best-corrected visual acuity and angiographic characteristics were evaluated after 6 months. Results: The mean logarithm of the minimum angle of resolution best-corrected ...
Source: RETINA - April 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
Conclusion: Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA. (Source: RETINA)
Source: RETINA - April 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 24, 2019 Category: Cancer & Oncology Source Type: research

Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
ConclusionsInterpretation of cost-effectiveness data should be treated with caution in this case; details of the therapeutic regimen, such as dosage and frequency, and clinical efficacy of the treatments should be considered in relation to policy-making decisions. Given the scarcity of resources, the ever-increasing significance of health technology assessment, and the substantial differences in the methodologies of the studies presented in this review, there is a pressing need for more advanced and standardised approaches to assessing the effectiveness and cost effectiveness of the emerging anti-VEGF pharmacotherapies for...
Source: PharmacoEconomics - April 22, 2019 Category: Health Management Source Type: research

Resolution of Large Choroidal Tuberculoma following Monotherapy with Intravitreal Ranibizumab.
CONCLUSIONS: Ranibizumab monotherapy may lead in complete regression of vascularized tubercular choroidal granulomas without the need of adjunctive ATT and corticosteroids. After intravitreal injection of ranibizumab, the lesion may be observed for regression over several weeks. PMID: 30986122 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - April 17, 2019 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study.
Authors: Woo SJ, Cho GE, Cho JH Abstract PURPOSE: To investigate the short-term efficacy and safety of ranibizumab in the routine clinical setting in patients with neovascular age-related macular degeneration and to analyze the associated factors for visual outcome. METHODS: This was a post-hoc analysis of a ranibizumab regulatory post-marketing surveillance study in which 4,136 patients were enrolled and followed for 12 weeks. Change in best-corrected visual acuity (BCVA), size of choroidal neovascularization, and the presence of hemorrhage and exudate were analyzed and the association between BCVA change and ...
Source: Korean Journal of Ophthalmology : KJO - April 14, 2019 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

A Comparison study of Ranibizumab and Aflibercept in patients with naive diabetic macular edema in presence of serous retinal detachment.
Abstract AIM OF THE STUDY: The aim of this study is to compare the efficacy of intravitreal injection of Aflibercept and Ranibizumab in the treatment of naive diabetic macular edema (DME) with serous retinal detachment (SRD). MATERIALS AND METHODS: In this prospective, non- randomized-cohort study, 60 eyes with DME with SRD were divided into two groups: group1 consisted of 30 eyes treated with intravitreal injection of 0.5 mg/0.1 mL Ranibizumab (IVR) and group2 consisted of 30 eyes treated with intravitreal injection of 2 mg/0.05 mL Aflibercept (IVA). After three sequential injections with 30-40 day interval ...
Source: Current Eye Research - April 14, 2019 Category: Opthalmology Authors: Kaldırım H, Yazgan S, Kırgız A, Atalay K, Savur F Tags: Curr Eye Res Source Type: research